公司资料
Viking Therapeutics 股价、新闻与催化剂
- 股票代码:
- VKTX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
33.23 USD (-1.95%)
收盘价
最后更新: 2026年8月24日
3.4B USD
市值
股价为何变动
As of Aug 24, 2026, VKTX closed down 1.95% at $33.23. No new same-company headline was identified in the current news window.
公司概览
Obesity-Focused Metabolic Biotech
Viking Therapeutics is a clinical-stage biotechnology company advancing therapies for obesity and metabolic disease. Its pipeline is led by VK2735 and supported by additional obesity, liver/metabolic, and rare disease programs.
Lead Franchise: VK2735
VK2735 is a wholly owned dual GLP-1/GIP receptor agonist in development for obesity and related metabolic disorders. Viking is developing both subcutaneous and oral formulations, giving the program a differentiated profile across induction, long-term maintenance, and patient preference.
Phase 3 and Oral Development
The subcutaneous formulation is being evaluated in the Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials, both of which are fully enrolled. Viking is also preparing to start Phase 3 trials of oral VK2735 in the fourth quarter of 2026, positioning the oral program as a potential first oral dual GLP-1/GIP agonist.
Broader Metabolic Pipeline
Viking is expanding the obesity franchise with VK3019, an investigational dual amylin and calcitonin receptor agonist now in Phase 1. The company also lists VK2809, an oral thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for X-linked adrenoleukodystrophy.
未来催化剂
- VK2735 maintenance dosing data expected in the third quarter of 2026.
- Phase 3 oral VK2735 trial initiation expected in the fourth quarter of 2026.
- VK3019 Phase 1 single-ascending-dose study readouts when the trial reports.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。